Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIMOTHY G MORIARTY

Allopathic & Osteopathic Physicians General Practice

NPI
1578539805
CMS profile
116420
Location
PANAMA CITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,569.25

39 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,111.60 37
Travel and Lodging $457.65 2

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIMOTHY G MORIARTY

NPI 1578539805 · CMS profile ID 116420

Allopathic & Osteopathic Physicians / General Practice

PANAMA CITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578539805?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIMOTHY G MORIARTY, NPI 1578539805, CMS profile ID 116420. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578539805?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). TIMOTHY G MORIARTY, NPI 1578539805, CMS profile ID 116420. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578539805?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
TIMOTHY G MORIARTY, NPI 1578539805, CMS profile ID 116420, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1578539805?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

39 matching records · $1,569.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 39 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–39 of 39.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mylan Specialty L.P. $23.1411/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694814679 CMS
GlaxoSmithKline, LLC. $22.4911/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670687595 CMS
GlaxoSmithKline, LLC. $10.9811/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671252555 CMS
AstraZeneca Pharmaceuticals LP $14.9611/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685792493 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $69.6111/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700105793 CMS
GlaxoSmithKline, LLC. $17.9410/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670793433 CMS
AstraZeneca Pharmaceuticals LP $324.0510/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685022815 CMS
AstraZeneca Pharmaceuticals LP $344.0010/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685110877 CMS
AstraZeneca Pharmaceuticals LP $133.6010/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685184429 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.8610/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700041695 CMS
GlaxoSmithKline, LLC. $20.6410/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670911849 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $29.9109/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700105795 CMS
GlaxoSmithKline, LLC. $24.5809/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670832888 CMS
AstraZeneca Pharmaceuticals LP $14.9009/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685361437 CMS
GlaxoSmithKline, LLC. $23.4309/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671451035 CMS
GlaxoSmithKline, LLC. $20.4208/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671420215 CMS
AstraZeneca Pharmaceuticals LP $18.3008/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685338879 CMS
AstraZeneca Pharmaceuticals LP $85.5507/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685304715 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.5407/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700105797 CMS
AstraZeneca Pharmaceuticals LP $14.4307/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685767121 CMS
GlaxoSmithKline, LLC. $22.1306/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671470145 CMS
GlaxoSmithKline, LLC. $19.7606/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670720969 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $3.6006/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700105799 CMS
Regeneron Healthcare Solutions, Inc. $14.0906/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673443001 CMS
GENZYME CORPORATION $18.9105/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694028203 CMS
GlaxoSmithKline, LLC. $18.7304/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671245935 CMS
GlaxoSmithKline, LLC. $20.4504/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670364527 CMS
AstraZeneca Pharmaceuticals LP $17.6404/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685120697 CMS
Mylan Specialty L.P. $18.1404/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694781967 CMS
GlaxoSmithKline, LLC. $16.4903/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671418865 CMS
AstraZeneca Pharmaceuticals LP $20.0103/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685928039 CMS
GlaxoSmithKline, LLC. $16.9903/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670370133 CMS
GlaxoSmithKline, LLC. $15.6302/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671471369 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.2402/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700105791 CMS
GlaxoSmithKline, LLC. $16.9902/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670763681 CMS
GlaxoSmithKline, LLC. $9.5402/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671330853 CMS
GlaxoSmithKline, LLC. $20.8901/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671454273 CMS
GlaxoSmithKline, LLC. $16.0201/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671440063 CMS
AstraZeneca Pharmaceuticals LP $11.6701/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685976027 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,569.25 39

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $81,304.10 30
PY2020 Principal investigator $303,748.50 51
PY2019 Recipient $1,188.88 12
PY2019 Principal investigator $261,356.49 38

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,284.15 12/31/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 684980251
Principal investigator 1 SANOFI US SERVICES INC. $3,838.73 11/26/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691608353
Principal investigator 1 SANOFI US SERVICES INC. $220.00 11/26/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691608359
Principal investigator 1 SANOFI US SERVICES INC. $3,469.65 11/12/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691603575
Principal investigator 1 SANOFI US SERVICES INC. $1,421.25 11/12/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691603973
Principal investigator 1 SANOFI US SERVICES INC. $475.00 11/12/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691603987
Principal investigator 1 SANOFI US SERVICES INC. $6,309.91 11/12/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691604177
Principal investigator 1 SANOFI US SERVICES INC. $3,075.30 11/12/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691604183
Principal investigator 1 SANOFI US SERVICES INC. $2,107.90 11/12/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691606159
Principal investigator 1 GlaxoSmithKline, LLC. $475.00 10/29/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH ASSOCIATES
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO C No dispute reported 06/30/2026 669974787
Principal investigator 1 Genentech, Inc. $700.00 10/09/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH
PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA No dispute reported 06/30/2026 681067541
Principal investigator 1 Genentech, Inc. $3,837.00 10/09/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH
PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA No dispute reported 06/30/2026 681072272
Principal investigator 1 SANOFI US SERVICES INC. $11,195.56 10/09/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691606348
Principal investigator 1 GlaxoSmithKline, LLC. $1,600.00 09/24/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH ASSOCIATES
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO C No dispute reported 06/30/2026 669974331
Principal investigator 1 SANOFI US SERVICES INC. $2,214.00 09/09/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691605935
Principal investigator 1 SANOFI US SERVICES INC. $16,543.59 09/09/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691605945
Principal investigator 1 Genentech, Inc. $170.00 09/02/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH
PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA No dispute reported 06/30/2026 681103425
Principal investigator 1 Genentech, Inc. $1,597.05 08/01/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH
PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA No dispute reported 06/30/2026 681075063
Principal investigator 1 GlaxoSmithKline, LLC. $2,800.00 07/02/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH ASSOCIATES
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO C No dispute reported 06/30/2026 669957513
Principal investigator 1 SANOFI US SERVICES INC. $2,842.50 07/02/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691605382
Principal investigator 1 SANOFI US SERVICES INC. $1,421.25 07/02/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691605385
Recipient SANOFI US SERVICES INC. $25.07 06/21/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691557497
Recipient SANOFI US SERVICES INC. $22.47 06/21/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691557501
Recipient SANOFI US SERVICES INC. $45.01 06/20/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691557353
Recipient SANOFI US SERVICES INC. $49.23 06/20/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691557355
Recipient SANOFI US SERVICES INC. $28.95 06/20/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691611612
Principal investigator 1 Genentech, Inc. $585.14 06/19/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH
PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA No dispute reported 06/30/2026 681089311
Recipient SANOFI US SERVICES INC. $43.83 06/19/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691557345
Recipient SANOFI US SERVICES INC. $99.50 06/19/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691557347
Recipient SANOFI US SERVICES INC. $37.38 06/19/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691557351
Recipient SANOFI US SERVICES INC. $235.31 06/18/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691557331
Recipient SANOFI US SERVICES INC. $256.68 06/18/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691557335
Recipient SANOFI US SERVICES INC. $320.37 06/18/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691557341
Recipient SANOFI US SERVICES INC. $25.08 06/18/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi No dispute reported 06/30/2026 691557494
Principal investigator 1 SANOFI US SERVICES INC. $9,900.00 06/03/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691605165
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 06/03/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 691605173
Principal investigator 1 Genentech, Inc. $924.00 05/24/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH
SEVERE PATIENTS UNCONTROLLED ON ICS 2ND CONTROLLER No dispute reported 06/30/2026 681092683
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 04/18/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH ASSOCIATES
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO C No dispute reported 06/30/2026 669959051
Principal investigator 1 Genentech, Inc. $2,492.10 04/05/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH
PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA No dispute reported 06/30/2026 681090685
Principal investigator 1 Genentech, Inc. $1,957.50 03/13/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH
PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA No dispute reported 06/30/2026 681078349
Principal investigator 1 Genentech, Inc. $700.00 03/01/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH
PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA No dispute reported 06/30/2026 681090683
Principal investigator 1 GlaxoSmithKline, LLC. $1,280.00 02/28/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH ASSOCIATES
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO C No dispute reported 06/30/2026 669971965
Principal investigator 1 Hikma Pharmaceuticals USA $8,599.75 02/14/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641062677
Principal investigator 1 Genentech, Inc. $259.66 02/13/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH
PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA No dispute reported 06/30/2026 681092407
Principal investigator 1 Genentech, Inc. $48.29 02/08/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH
PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA No dispute reported 06/30/2026 681081707
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 02/07/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH ASSOCIATES
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO C No dispute reported 06/30/2026 669956791
Principal investigator 1 AstraZeneca Pharmaceuticals LP $97,712.19 01/22/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 684980241
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,787.90 01/22/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) No dispute reported 06/30/2026 684980247
Principal investigator 1 Hikma Pharmaceuticals USA $12,470.02 01/16/2019 Non-covered Recipient Entity
Emerald Coast Research Associates
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641062675
Principal investigator 1 Genentech, Inc. $2,492.10 01/11/2019 Non-covered Recipient Entity
EMERALD COAST RESEARCH
PH IIB OF MSTT1041A IN SEVERE UNCONTROLLED ASTHMA No dispute reported 06/30/2026 681080127